These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32757299)

  • 1. Strategies and Recommendations for Using a Data-Driven and Risk-Based Approach in the Selection of First-in-Human Starting Dose: An International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Assessment.
    Leach MW; Clarke DO; Dudal S; Han C; Li C; Yang Z; Brennan FR; Bailey WJ; Chen Y; Deslandes A; Loberg LI; Mayawala K; Rogge MC; Todd M; Chemuturi NV
    Clin Pharmacol Ther; 2021 Jun; 109(6):1395-1415. PubMed ID: 32757299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics.
    Agoram BM
    Br J Clin Pharmacol; 2009 Feb; 67(2):153-60. PubMed ID: 19076987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies.
    Muller PY; Milton M; Lloyd P; Sims J; Brennan FR
    Curr Opin Biotechnol; 2009 Dec; 20(6):722-9. PubMed ID: 19896825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-in-human dose: current status review for better future perspectives.
    Mishra A; Sarangi SC; Reeta K
    Eur J Clin Pharmacol; 2020 Sep; 76(9):1237-1243. PubMed ID: 32488334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach.
    Schaller TH; Snyder DJ; Spasojevic I; Gedeon PC; Sanchez-Perez L; Sampson JH
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32273346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013.
    Suh HY; Peck CC; Yu KS; Lee H
    Drug Des Devel Ther; 2016; 10():4005-4016. PubMed ID: 27994442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection.
    Saber H; Del Valle P; Ricks TK; Leighton JK
    Regul Toxicol Pharmacol; 2017 Nov; 90():144-152. PubMed ID: 28887049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno-Safety Technical Committee (ITC).
    Matsumoto M; Polli JR; Swaminathan SK; Datta K; Kampershroer C; Fortin MC; Salian-Mehta S; Dave R; Yang Z; Arora P; Hiura M; Suzuki M; Brennan FR; Sathish J
    Clin Pharmacol Ther; 2024 Jun; ():. PubMed ID: 38847597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of the relationship between a starting dose in first-in-human studies and no observed adverse effect level in nonclinical studies.
    Sato A; Narukawa M
    Int J Clin Pharmacol Ther; 2014 Sep; 52(9):770-6. PubMed ID: 25034619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An IQ consortium analysis of starting dose selection for oncology small molecule first-in-patient trials suggests an alternative NOAEL-based method can be safe while reducing time to the recommended phase 2 dose.
    Jessen BA; Cornwell P; Redmond S; Visalli T; Lemper M; Bunch T; Hart T
    Cancer Chemother Pharmacol; 2023 Dec; 92(6):455-464. PubMed ID: 37505272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies.
    Muller PY; Brennan FR
    Clin Pharmacol Ther; 2009 Mar; 85(3):247-58. PubMed ID: 19177065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of phase I clinical drug trials: Influence of organizational management factors.
    Zhao Y; Yang Q; Zhang X
    J Clin Pharm Ther; 2020 Oct; 45(5):968-975. PubMed ID: 32053745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method.
    Song L; Xue J; Zhang J; Li S; Liu D; Zhou T
    Eur J Pharm Sci; 2021 Mar; 158():105584. PubMed ID: 33039565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An FDA oncology analysis of immune activating products and first-in-human dose selection.
    Saber H; Gudi R; Manning M; Wearne E; Leighton JK
    Regul Toxicol Pharmacol; 2016 Nov; 81():448-456. PubMed ID: 27743776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Industry Perspective on the 2017 EMA Guideline on First-in-Human and Early Clinical Trials.
    DeGeorge J; Robertson S; Butler L; Derzi M; Stoch SA; Diaz D; Hartke J; Guzzie-Peck P; Mortimer-Cassen E; Bogdanffy M; Will Y; Greene N
    Clin Pharmacol Ther; 2018 Apr; 103(4):566-569. PubMed ID: 29285748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating the starting dose for entry into humans: principles and practice.
    Reigner BG; Blesch KS
    Eur J Clin Pharmacol; 2002 Feb; 57(12):835-45. PubMed ID: 11936701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model-informed drug development for immuno-oncology agonistic anti-GITR antibody GWN323: Dose selection based on MABEL and biologically active dose.
    Ji Y; Knee D; Chen X; Dang A; Mataraza J; Wolf B; Sy SKB
    Clin Transl Sci; 2022 Sep; 15(9):2218-2229. PubMed ID: 35731955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A brief survey of first-in-human studies.
    Wexler D; Bertelsen KM
    J Clin Pharmacol; 2011 Jul; 51(7):988-93. PubMed ID: 20671293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reprint of: Nonclinical species sensitivity to convulsions: An IQ DruSafe consortium working group initiative.
    DaSilva JK; Breidenbach L; Deats T; Li D; Treinen K; Dinklo T; Kervyn S; Teuns G; Traebert M; Hempel K
    J Pharmacol Toxicol Methods; 2020 Sep; 105():106919. PubMed ID: 33011055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA; Dorato MA
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.